# A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

> **NCT02694328** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 561 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ALKS 3831
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT02694328
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2018-11-07
- **Final completion:** 2018-11-07
- **Target enrollment:** 561 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694328, "A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02694328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*